Role of GLP-1 Agonists and SGLT-2 on Diabetes and Kidney Disease Post Liver Transplant The emergence of Glucagon-like peptide-1 receptor (GLP-1) agonists and Sodium-glucose cotransporter-2 (SGLT-2) inhibitors as glucose-lowering therapies has opened new therapeutic avenues for managing patients with diabetic kidney disease
I'm, I'm thrilled to hear
The FDA is not bound to follow the committees advice, but it usually does
Chen adds
[DOI] [PMC free article] [PubMed] [Google Scholar] 118.Rasic D., Zenko Sever A., Rasic F., Strbe S., Rasic Z., Djuzel A., Duplancic B., Boban Blagaic A., Skrtic A., Seiwerth S., et al
Liraglutide (0.2 mg/kg) was intraperitoneally injected 45 min before performing insulin, glucose, and pyruvate tolerance tests (ITT, GTT and PTT respectively)